Evidence map›Paper›PMID 42203677›Full record

ArticleCancer science2026

First-In-Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck.

Nobuaki Matsubara, Ken Saijo, Yasushi Shimizu, Susumu Okano, Kenji Nakano, Naoki Nishio, Tomoyuki Otsuka, Hirofumi Kuno, Takuma Miura, Tomoki Kubota and 6 more

Abstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nobuaki MatsubaraDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.ORCID https://orcid.org/0000-0002-9203-4245
Ken SaijoDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.ORCID https://orcid.org/0000-0003-0179-3789
Yasushi ShimizuDepartment of Medical Oncology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
Susumu OkanoDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.ORCID https://orcid.org/0000-0001-6639-9753
Kenji NakanoDepartment of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Naoki NishioDepartment of Otorhinolaryngology, Nagoya University Hospital, Nagoya, Japan.
Tomoyuki OtsukaDepartment of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
Hirofumi KunoDepartment of Diagnostic Radiology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Takuma MiuraJapan and Asia Clinical Development Department, Eisai Co. Ltd., Tokyo, Japan.
Tomoki KubotaJapan and Asia Clinical Development Department, Eisai Co. Ltd., Tokyo, Japan.
Hiroki IkezawaClinical Data Science Department, Eisai Co. Ltd., Tokyo, Japan.
Yuko UmetsuClinical Pharmacology & Translational Research Department, Eisai Co. Ltd., Tokyo, Japan.
Ken ItoOncology Discovery Department, Eisai Co. Ltd., Ibaraki, Japan.ORCID https://orcid.org/0000-0002-6997-4271
Abraham ApfelClinical Data Science, Eisai Inc., Nutley, New Jersey, USA.
Yuanqing YeClinical Data Science, Eisai Inc., Nutley, New Jersey, USA.
Yoshitaka HonmaDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Funding

Eisai Co. Ltd.
6 · The paper itself

Abstract

The dose escalation part of the first-in-human study of E7130 in patients with advanced solid tumors determined the Recommended Phase 2 Dose (RP2D) of E7130 (480 μg/m

Indexed as

Antineoplastic AgentsCarcinoma, Transitional CellHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckUrinary Bladder NeoplasmsAdultAgedAged, 80 and overDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedProgression-Free SurvivalTreatment OutcomeAntineoplastic Agentsclinical trialPhase 1Phase 1 Clinical Trialsquamous cell carcinoma of the head and necktubulin modulatorsurinary bladder neoplasms

Identifiers

PMID42203677
PMCPMC13394766

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.